FDA Boots 15 Forgotten Drugs from Approval List Cleanly
Published Date: 3/12/2026
Notice
Summary
The FDA is officially pulling the plug on 15 drug approvals because the companies, including Watson Laboratories and others, told the FDA they stopped selling these medicines. This change kicks in on April 13, 2026, but companies can apply again if they want. No money penalties here—just a cleanup to keep things current and clear!
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Fifteen Generic Drug Approvals Withdrawn
The FDA is withdrawing approval of 15 abbreviated new drug applications (ANDAs) for listed generic medicines (examples include cimetidine, fluoxetine HCl, famotidine, sotalol HCl, paclitaxel injectable, doxazosin mesylate, gabapentin, bisoprolol fumarate/hydrochlorothiazide, and vinorelbine tartrate) as of April 13, 2026. The applicants told FDA they stopped marketing these products, and products in inventory on April 13, 2026 may still be dispensed until the inventory is depleted or the product expires.
Manufacturers May Refile; No Penalty
The FDA says the withdrawals are "without prejudice to refiling," so applicants may submit new ANDAs again if they choose. The applicants waived their opportunity for a hearing, and the notice describes this action as a cleanup rather than a monetary penalty.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11762 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products
The FDA is asking for approval to keep collecting info from seafood processors and importers to make sure fish products are safe using a system called HACCP. This affects anyone who processes or imports fish and requires them to keep records showing they’re following safety rules. Comments on this plan are open until July 13, 2026, and there’s no new cost, just a continuation of current paperwork.
2026-11739 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
2026-11760 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
2026-11740 — Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System
The FDA is officially putting the Spinal Muscular Atrophy (SMA) newborn screening test into class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the test safer and easier to get to babies who need it, starting June 11, 2026, with the classification effective since November 2022. Labs and device makers will benefit from clearer rules and faster access, helping catch SMA early without extra costs or delays.
2026-11589 — Medical Devices; Ear, Nose, and Throat Devices; Classification of the Combined Acoustic and Electrical External Stimulation Device for the Relief of Tinnitus
The FDA has officially placed the combined acoustic and electrical external stimulation device for tinnitus relief into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps patients get access to this innovative device faster and ensures it’s safe and effective. The new classification is effective June 10, 2026, with the rules applying retroactively from March 6, 2023.
2026-11578 — Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information
The FDA just gave a thumbs-up to adding bemotrizinol as a new active ingredient in sunscreens, letting it be used up to 6% concentration. This means sunscreen makers can now include this ingredient, which is safe and effective, in their products. The change is official as of June 10, 2026, and could lead to better sun protection options without extra costs for consumers.
Previous / Next Documents
Previous: 2026-04796 — Privacy Act of 1974; Matching Program
The FCC and USAC are teaming up with HUD to double-check who qualifies for Lifeline and the Affordable Connectivity Program, which help low-income families get affordable internet and phone service. This new computer matching program starts April 13, 2026, runs for 18 months, and aims to keep benefits fair and accurate. If you’re part of these programs, this means better verification but no changes to your current support.
Next: 2026-04800 — Self-Regulatory Organizations; CME Securities Clearing Inc.; Notice of Filing of Proposed Rule Change To Modify the CME Securities Clearing Inc. Amended and Restated By-Laws, Board of Directors Charter, Risk Management Committee Charter, Nominating Committee Charter, and Audit Committee Charter
CME Securities Clearing Inc. is updating its rules and committee guidelines to get ready for launching new clearing services. These changes affect the Board of Directors and key committees, making sure everything runs smoothly and safely. The updates don’t signal any immediate cost changes but set the stage for a strong, well-organized future starting soon.